SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
5.12 / 10
Netural
Capital flow assessment yields 6.93/10, denoting robust fund flow characteristics. Strengths in Small and Large trends confront pressures from overall, block, Medium, and Extra-large patterns, resulting in positive liquidity outlook. Analyst sentiment reflects overwhelmingly bullish analyst consensus with strong conviction. The rating profile includes Strong Buy(100.0%) from 3 analytical reports, supported by 3.32 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-18
InstitutionChardan Capital
Times predicted6
Historical Win Rate66.7%
What is the analyst consensus for SABS?
- SABS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.12/10 (Netural).
